| Dr Rodrigo Nardi, MD | |
|
200 High Service Ave, North Providence, RI 02904-5113 | |
| (401) 456-3000 | |
| Not Available |
| Full Name | Dr Rodrigo Nardi |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 14 Years |
| Location | 200 High Service Ave, North Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679837876 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD15465 (Rhode Island) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Comprehensive Community Action, Inc. | 0749176055 | 22 |
| Northeast Health Services Llc | 6901866706 | 210 |
News Archive
A supervised drug-injection facility in Vancouver, Canada, will remain open until December 2007 after it received a reprieve on Friday from Health Minister Tony Clement, Toronto's Globe and Mail reports (Fong, Globe and Mail, 9/2).
CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill).
EMC Corporation, the world leader in information infrastructure solutions, today announced that Aspirus, a non-profit system of hospitals, clinics and other healthcare facilities with more than 4,200 employees and more than 400 licensed inpatient beds in its system, is helping its practitioners streamline workflows while reducing IT administrative costs leveraging EMC solutions and services for data center consolidation and virtualization.
In a development that sheds new light on the pathology of Alzheimer's disease (AD), a team of Whitehead Institute scientists has identified connections between genetic risk factors for the disease and the effects of a peptide toxic to nerve cells in the brains of AD patients.
› Verified 4 days ago
| Entity Name | Northeast Health Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225067481 PECOS PAC ID: 6901866706 Enrollment ID: O20041015000643 |
News Archive
A supervised drug-injection facility in Vancouver, Canada, will remain open until December 2007 after it received a reprieve on Friday from Health Minister Tony Clement, Toronto's Globe and Mail reports (Fong, Globe and Mail, 9/2).
CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill).
EMC Corporation, the world leader in information infrastructure solutions, today announced that Aspirus, a non-profit system of hospitals, clinics and other healthcare facilities with more than 4,200 employees and more than 400 licensed inpatient beds in its system, is helping its practitioners streamline workflows while reducing IT administrative costs leveraging EMC solutions and services for data center consolidation and virtualization.
In a development that sheds new light on the pathology of Alzheimer's disease (AD), a team of Whitehead Institute scientists has identified connections between genetic risk factors for the disease and the effects of a peptide toxic to nerve cells in the brains of AD patients.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rodrigo Nardi, MD 200 High Service Ave, North Providence, RI 02904-5113 Ph: (401) 456-3000 | Dr Rodrigo Nardi, MD 200 High Service Ave, North Providence, RI 02904-5113 Ph: (401) 456-3000 |
News Archive
A supervised drug-injection facility in Vancouver, Canada, will remain open until December 2007 after it received a reprieve on Friday from Health Minister Tony Clement, Toronto's Globe and Mail reports (Fong, Globe and Mail, 9/2).
CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill).
EMC Corporation, the world leader in information infrastructure solutions, today announced that Aspirus, a non-profit system of hospitals, clinics and other healthcare facilities with more than 4,200 employees and more than 400 licensed inpatient beds in its system, is helping its practitioners streamline workflows while reducing IT administrative costs leveraging EMC solutions and services for data center consolidation and virtualization.
In a development that sheds new light on the pathology of Alzheimer's disease (AD), a team of Whitehead Institute scientists has identified connections between genetic risk factors for the disease and the effects of a peptide toxic to nerve cells in the brains of AD patients.
› Verified 4 days ago
Ronald C Gobeil, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 200 High Service Avenue, Marian Hall 1st Floor, North Providence, RI 02904 Phone: 401-456-3649 Fax: 401-752-8116 | |
Robert James Zielinski, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 17 Hunters Run, North Providence, RI 02904 Phone: 401-323-8065 |